Latest advancements and investigational therapeutics in chronic urticaria medicine: Emek Kocatürk

There are currently multiple therapeutics showing promise in clinical trials for chronic urticaria including anti-IL-4 monoclonal antibodies, Bruton’s tyrosine kinase (BTK) inhibitors and anti-KIT-monoklonal antibodies. touchDERMATOLOGY were delighted to speak with Expert Faculty member Professor Emek Kocatürk (Koç University School of Medicine, Istanbul, Turkey & Charite University Institute of Allergology) to discuss the latest advancements and investigational therapeutics in chronic urticaria medicine. The presentation 'Incoming treatments for Chronic Urticaria' (Presentation ID D2T05.3C) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress. Questions Could you give us a brief overview of the current guidelines for chronic urticaria management? (0:30) What investigational therapeutics show promise for chronic urticaria? (3:49) Disclosures: Emek Kocatürk discloses serving on advisory boards for Novartis, and Menarini. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

Ligelizumab is a monoclonal antibody recently investigated in the phase 3 PEARL-1 and PEARL-2 studies for the treatment of chronic spontaneous urticaria (ClinicalTrials.gov Identifiers: NCT03580369 & NCT03580356). In this touchIMMUNOLOGY interview, we spoke with Dr. Luis Felipe C. Ensina (Federal University of São Paulo, São Paulo, Brazil) around the rationale for investigating ligelizumab in this […]

Phase 2 results of remibrutinib for chronic spontaneous urticaria (CSU) show a fast and sustained response to treatment. While the phase 3b trial is ongoing, touchIMMUNOLOGY were delighted to speak with Prof. Marcus Maurer (Professor of Dermatology and Allergy, Charité – Universitätsmedizin Berlin) about the rationale for studying remibrutinib in relation to CSU and the ongoing […]